-
Featured Authors
-
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Events
Latest From Events
Delivering the Right Dose, Less Often
Biologics are a growing area of drug development, including life-threatening and life-changing disorders such as cancer and rheumatoid arthritis. However, many biologics have short half-lives, and need to be dosed daily. To make them more convenient to use, as well as safer and more effective, researchers are developing delivery systems that keep the biologics in the body for longer, reducing the frequency of dosing. Swedish company Affibody is using the natural affinity of a naturally-occurring Read More >
Acts of Support
Because small biotechnology companies do not have product revenue, burdensome regulations have an outsized effect on them. One-size-fits-all compliance requirements – such as Section 404(b) of the Sarbanes-Oxley Act (SOX) – divert funds from the lab and slow the development process. We have already seen the benefits that positive legislative reform can have for capital formation for emerging growth companies (EGCs). The JOBS Act has led to a sea change in the regulatory landscape and Read More >
In Memory of Sandi Dennis
Last September, BIO and the industry lost a dear friend and one of the nation’s top regulatory attorneys – Sandi Dennis – after a long battle with cancer. Sandi served as the deputy general counsel for healthcare at BIO. She focused on educating biotechnology companies about emerging legal and policy issues affecting the development of ground-breaking new medicines, and advocating on their behalf with Congress and executive agencies to help expedite the approval of treatments Read More >
Richard Branson’s Biofuel Enthusiasm
The serial entrepreneur believes in investing in many alternative sources of energy including biofuels. Legendary entrepreneur/business leader Sir Richard Charles Nicholas Branson is known for pushing the envelope with his Virgin Group. More than 400 companies exist under the moniker, the most well-known including the Virgin Records music label, the American airline Virgin America, cell phone provider Virgin Mobile, and Virgin Galactic, the world’s first commercial spaceline. Branson’s initiatives toward environmental sustainability and climate change Read More >
Reimagined and Reinvented
We are excited that you are joining us for the 2014 BIO International Convention. As you have seen, we are doing things a little differently this year. We have revamped and improved the Convention to make it more engaging, more informative and more productive. We listened to your feedback and have added new educational Specialty Forums. Our Forums will offer cohesive programming in which participation in all sessions is recommended, allowing for a deeper dive Read More >
